177 related articles for article (PubMed ID: 33439362)
1. Efficacy of adjunctive D-Cycloserine for the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
Kuppili PP; Menon V; Sathyanarayanan G; Sarkar S; Andrade C
J Neural Transm (Vienna); 2021 Feb; 128(2):253-262. PubMed ID: 33439362
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.
Singh SP; Singh V
CNS Drugs; 2011 Oct; 25(10):859-85. PubMed ID: 21936588
[TBL] [Abstract][Full Text] [Related]
3. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis.
Tuominen HJ; Tiihonen J; Wahlbeck K
Schizophr Res; 2005 Jan; 72(2-3):225-34. PubMed ID: 15560967
[TBL] [Abstract][Full Text] [Related]
4. Glutamatergic drugs for schizophrenia.
Tuominen HJ; Tiihonen J; Wahlbeck K
Cochrane Database Syst Rev; 2006 Apr; (2):CD003730. PubMed ID: 16625590
[TBL] [Abstract][Full Text] [Related]
5. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Buchanan RW; Javitt DC; Marder SR; Schooler NR; Gold JM; McMahon RP; Heresco-Levy U; Carpenter WT
Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
[TBL] [Abstract][Full Text] [Related]
6. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.
Goff DC; Tsai G; Levitt J; Amico E; Manoach D; Schoenfeld DA; Hayden DL; McCarley R; Coyle JT
Arch Gen Psychiatry; 1999 Jan; 56(1):21-7. PubMed ID: 9892252
[TBL] [Abstract][Full Text] [Related]
7. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients.
Goff DC; Herz L; Posever T; Shih V; Tsai G; Henderson DC; Freudenreich O; Evins AE; Yovel I; Zhang H; Schoenfeld D
Psychopharmacology (Berl); 2005 Apr; 179(1):144-50. PubMed ID: 15502972
[TBL] [Abstract][Full Text] [Related]
8. D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia.
Rosse RB; Fay-McCarthy M; Kendrick K; Davis RE; Deutsch SI
Clin Neuropharmacol; 1996 Oct; 19(5):444-50. PubMed ID: 8889288
[TBL] [Abstract][Full Text] [Related]
9. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study.
van Berckel BN; Evenblij CN; van Loon BJ; Maas MF; van der Geld MA; Wynne HJ; van Ree JM; Kahn RS
Neuropsychopharmacology; 1999 Aug; 21(2):203-10. PubMed ID: 10432468
[TBL] [Abstract][Full Text] [Related]
10. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia.
Goff DC; Henderson DC; Evins AE; Amico E
Biol Psychiatry; 1999 Feb; 45(4):512-4. PubMed ID: 10071726
[TBL] [Abstract][Full Text] [Related]
11. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
[TBL] [Abstract][Full Text] [Related]
12. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis.
Tsai GE; Lin PY
Curr Pharm Des; 2010; 16(5):522-37. PubMed ID: 19909229
[TBL] [Abstract][Full Text] [Related]
13. D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity.
Goff DC
Curr Neuropharmacol; 2017; 15(1):21-34. PubMed ID: 26915421
[TBL] [Abstract][Full Text] [Related]
14. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study.
Goff DC; Cather C; Gottlieb JD; Evins AE; Walsh J; Raeke L; Otto MW; Schoenfeld D; Green MF
Schizophr Res; 2008 Dec; 106(2-3):320-7. PubMed ID: 18799288
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis.
Heresco-Levy U; Javitt DC
Schizophr Res; 2004 Feb; 66(2-3):89-96. PubMed ID: 15061240
[TBL] [Abstract][Full Text] [Related]
16. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia.
Goff DC; Tsai G; Manoach DS; Coyle JT
Am J Psychiatry; 1995 Aug; 152(8):1213-5. PubMed ID: 7625475
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of
Goh KK; Wu TH; Chen CH; Lu ML
J Psychopharmacol; 2021 Mar; 35(3):236-252. PubMed ID: 33406959
[TBL] [Abstract][Full Text] [Related]
18. D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia.
Evins AE; Amico E; Posever TA; Toker R; Goff DC
Schizophr Res; 2002 Jul; 56(1-2):19-23. PubMed ID: 12084415
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence.
Correll CU; Rubio JM; Inczedy-Farkas G; Birnbaum ML; Kane JM; Leucht S
JAMA Psychiatry; 2017 Jul; 74(7):675-684. PubMed ID: 28514486
[TBL] [Abstract][Full Text] [Related]
20. Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study.
Takiguchi K; Uezato A; Itasaka M; Atsuta H; Narushima K; Yamamoto N; Kurumaji A; Tomita M; Oshima K; Shoda K; Tamaru M; Nakataki M; Okazaki M; Ishiwata S; Ishiwata Y; Yasuhara M; Arima K; Ohmori T; Nishikawa T
BMC Psychiatry; 2017 Jul; 17(1):249. PubMed ID: 28701225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
